|
rs11568821
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The findings revealed that <i>PD-1</i> rs2227981 and rs11568821 polymorphisms significantly decreased the overall cancer risk (Odds Ratio (OR) = 0.82, 95% CI = 0.68-0.99, <i>p</i> = 0.04, TT vs. CT+CC; OR = 0.79, 95% CI = 0.67-0.94, <i>p</i> = 0.006, AG vs. GG, and OR = 0.82, 95% CI = 0.70-0.96, <i>p</i> = 0.020, AG+AA vs. GG, respectively), while <i>PD-1</i> rs7421861 polymorphism significantly increased the risk of developing cancer (OR = 1.16, 95% CI = 1.02-1.33, <i>p</i> = 0.03, CT vs. TT).
|
31405171 |
2019 |
|
rs2227981
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The findings revealed that <i>PD-1</i> rs2227981 and rs11568821 polymorphisms significantly decreased the overall cancer risk (Odds Ratio (OR) = 0.82, 95% CI = 0.68-0.99, <i>p</i> = 0.04, TT vs. CT+CC; OR = 0.79, 95% CI = 0.67-0.94, <i>p</i> = 0.006, AG vs. GG, and OR = 0.82, 95% CI = 0.70-0.96, <i>p</i> = 0.020, AG+AA vs. GG, respectively), while <i>PD-1</i> rs7421861 polymorphism significantly increased the risk of developing cancer (OR = 1.16, 95% CI = 1.02-1.33, <i>p</i> = 0.03, CT vs. TT).
|
31405171 |
2019 |
|
rs7421861
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The findings revealed that <i>PD-1</i> rs2227981 and rs11568821 polymorphisms significantly decreased the overall cancer risk (Odds Ratio (OR) = 0.82, 95% CI = 0.68-0.99, <i>p</i> = 0.04, TT vs. CT+CC; OR = 0.79, 95% CI = 0.67-0.94, <i>p</i> = 0.006, AG vs. GG, and OR = 0.82, 95% CI = 0.70-0.96, <i>p</i> = 0.020, AG+AA vs. GG, respectively), while <i>PD-1</i> rs7421861 polymorphism significantly increased the risk of developing cancer (OR = 1.16, 95% CI = 1.02-1.33, <i>p</i> = 0.03, CT vs. TT).
|
31405171 |
2019 |
|
rs11568821
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Frequently studied PD-1 polymorphisms, PD-1.1 (rs36084323), PD-1.3 (rs11568821), PD-1.5 (rs2227981), PD-1.9 (rs2227982), and PD-1 rs7421861, and their associations in the risk of susceptibility to different types of cancer are mentioned in this review, as are studies highlighting the significance of conducting genetic association studies in different ethnic populations.
|
28642997 |
2018 |
|
rs2227981
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Frequently studied PD-1 polymorphisms, PD-1.1 (rs36084323), PD-1.3 (rs11568821), PD-1.5 (rs2227981), PD-1.9 (rs2227982), and PD-1 rs7421861, and their associations in the risk of susceptibility to different types of cancer are mentioned in this review, as are studies highlighting the significance of conducting genetic association studies in different ethnic populations.
|
28642997 |
2018 |
|
rs7421861
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Frequently studied PD-1 polymorphisms, PD-1.1 (rs36084323), PD-1.3 (rs11568821), PD-1.5 (rs2227981), PD-1.9 (rs2227982), and PD-1 rs7421861, and their associations in the risk of susceptibility to different types of cancer are mentioned in this review, as are studies highlighting the significance of conducting genetic association studies in different ethnic populations.
|
28642997 |
2018 |
|
rs11568821
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The meta-analysis suggests that the PDCD-1.5 (rs2227981) and PDCD-1.3 (rs11568821) polymorphisms are associated with susceptibility of cancer.
|
27749524 |
2016 |
|
rs11568821
|
|
|
0.040 |
GeneticVariation |
BEFREE |
For PD-1.3 (rs11568821) polymorphism, we found different cancer susceptibilities between GA vs. GG and AA vs. AG+GG genetic models, and no associations between AA vs. GG, AA+AG vs. GG genetic models or A vs. G allele and cancer risks.
|
27031235 |
2016 |
|
rs2227981
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In general, our results firstly indicated that PD-1.5 (rs2227981) polymorphism is associated a strongly decreased risk of cancers.
|
27031235 |
2016 |
|
rs2227981
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The meta-analysis suggests that the PDCD-1.5 (rs2227981) and PDCD-1.3 (rs11568821) polymorphisms are associated with susceptibility of cancer.
|
27749524 |
2016 |
|
rs7421861
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The results of meta-analysis: the PDCD-1.5 (rs2227981) and PDCD-1.3 (rs11568821) polymorphisms were associated with decreased risk of cancer (rs2227981: OR = 0.75, 95% CI: 0.64-0.86, P < 0.0001 for TT vs TC + CC; rs11568821: OR = 0.79, 95% CI: 0.65-0.96, P = 0.02 for TC vs TT), while no significant associations were found for the other 3 polymorphisms (PDCD-1.9 [rs2227982] polymorphism: OR = 1.03, 95% CI: 0.90-1.18, P = 0.66 for CC + TC vs TT; PDCD1 rs7421861 polymorphism: OR = 1.10, 95% CI: 0.96-1.25, P = 0.16 for CC + TC vs TT; PDCD-1.6 [rs10204525] polymorphism: OR = 0.93, 95% CI: 0.82-1.05, P = 0.24 for GG + GA vs AA).
|
27749524 |
2016 |
|
rs7421861
|
|
|
0.040 |
GeneticVariation |
BEFREE |
However, there were no significant associations between either PD-1.9 (rs2227982) or PD-1 rs7421861 polymorphisms and cancer risks in all genetic models and alleles.
|
27031235 |
2016 |
|
rs2227982
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Frequently studied PD-1 polymorphisms, PD-1.1 (rs36084323), PD-1.3 (rs11568821), PD-1.5 (rs2227981), PD-1.9 (rs2227982), and PD-1 rs7421861, and their associations in the risk of susceptibility to different types of cancer are mentioned in this review, as are studies highlighting the significance of conducting genetic association studies in different ethnic populations.
|
28642997 |
2018 |
|
rs2227982
|
|
|
0.030 |
GeneticVariation |
BEFREE |
However, there were no significant associations between either PD-1.9 (rs2227982) or PD-1 rs7421861 polymorphisms and cancer risks in all genetic models and alleles.
|
27031235 |
2016 |
|
rs2227982
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results of meta-analysis: the PDCD-1.5 (rs2227981) and PDCD-1.3 (rs11568821) polymorphisms were associated with decreased risk of cancer (rs2227981: OR = 0.75, 95% CI: 0.64-0.86, P < 0.0001 for TT vs TC + CC; rs11568821: OR = 0.79, 95% CI: 0.65-0.96, P = 0.02 for TC vs TT), while no significant associations were found for the other 3 polymorphisms (PDCD-1.9 [rs2227982] polymorphism: OR = 1.03, 95% CI: 0.90-1.18, P = 0.66 for CC + TC vs TT; PDCD1 rs7421861 polymorphism: OR = 1.10, 95% CI: 0.96-1.25, P = 0.16 for CC + TC vs TT; PDCD-1.6 [rs10204525] polymorphism: OR = 0.93, 95% CI: 0.82-1.05, P = 0.24 for GG + GA vs AA).
|
27749524 |
2016 |
|
rs36084323
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This meta-analysis demonstrates the PD-1 rs36084323 A > G polymorphism is associated with decreased cancer risk in Asian, and suggests it could potentially serve as a biomarker to screen high-risk individuals.
|
30249505 |
2018 |
|
rs36084323
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Frequently studied PD-1 polymorphisms, PD-1.1 (rs36084323), PD-1.3 (rs11568821), PD-1.5 (rs2227981), PD-1.9 (rs2227982), and PD-1 rs7421861, and their associations in the risk of susceptibility to different types of cancer are mentioned in this review, as are studies highlighting the significance of conducting genetic association studies in different ethnic populations.
|
28642997 |
2018 |
|
rs10204525
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The results of meta-analysis: the PDCD-1.5 (rs2227981) and PDCD-1.3 (rs11568821) polymorphisms were associated with decreased risk of cancer (rs2227981: OR = 0.75, 95% CI: 0.64-0.86, P < 0.0001 for TT vs TC + CC; rs11568821: OR = 0.79, 95% CI: 0.65-0.96, P = 0.02 for TC vs TT), while no significant associations were found for the other 3 polymorphisms (PDCD-1.9 [rs2227982] polymorphism: OR = 1.03, 95% CI: 0.90-1.18, P = 0.66 for CC + TC vs TT; PDCD1 rs7421861 polymorphism: OR = 1.10, 95% CI: 0.96-1.25, P = 0.16 for CC + TC vs TT; PDCD-1.6 [rs10204525] polymorphism: OR = 0.93, 95% CI: 0.82-1.05, P = 0.24 for GG + GA vs AA).
|
27749524 |
2016 |
|
rs10204525
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results demonstrate for the first time that the PD-1 rs10204525 polymorphism might contribute to susceptibility of ESCC and may therefore support the hypothesis that genetic variants, influencing T cell activity-associated gene regulation, may modify cancer risk.
|
24389076 |
2014 |